SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001564590-20-018879
Filing Date
2020-04-27
Accepted
2020-04-27 17:21:41
Documents
5
Effectiveness Date
2020-04-27

Document Format Files

Seq Description Document Type Size
1 DEFA14A aldx-defa14a_20200609.htm DEFA14A 98200
2 GRAPHIC g5ocv2g0fm0t000002.jpg GRAPHIC 102532
3 GRAPHIC g5ocv2g0fm0t000004.jpg GRAPHIC 37575
4 GRAPHIC g5ocv2g0fm0t000003.jpg GRAPHIC 46352
5 GRAPHIC g5ocv2g0fm0t000001.jpg GRAPHIC 76369
  Complete submission text file 0001564590-20-018879.txt   461922
Mailing Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421
Business Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421 781-761-4904
Aldeyra Therapeutics, Inc. (Filer) CIK: 0001341235 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-36332 | Film No.: 20821248
SIC: 2834 Pharmaceutical Preparations